We are live on ! Find out more
NAGE icon

Niagen Bioscience

79 hedge funds and large institutions have $45.2M invested in Niagen Bioscience in 2024 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more capital inflows, than outflows

Capital inflows: $17M | Capital outflows: $6.01M

119% more call options, than puts

Call options by funds: $379K | Put options by funds: $173K

75% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 16

33% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 15

18% more funds holding

Funds holding: 67 → 79 (+12)

4.48% more ownership

Funds ownership: 17.43% → 21.91% (+4.5%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
79
Holders Change
+12
Holders Change %
+17.91%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
28
Increased
20
Reduced
15
Closed
16
Calls
$379​K
Puts
$173​K
Net Calls
+$206​K
Net Calls Change
-⁠$48​K

NAGE Hedge Fund Activity: Q2 2024 in Review

79 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q2 2024, worth a combined $45.2M — down 1.1% from $45.7M a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new NAGE positions and 16 closed out — a net gain of 12 holders — while 20 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $7.41M. The largest seller was Millennium Management, cutting an estimated $1.31M.

  • 79 institutional investors held Niagen Bioscience (NAGE) as of Q2 2024, up from 67 in Q1 2024.
  • Funds reported $45.2M of Niagen Bioscience stock for Q2 2024, down 1.1% quarter-over-quarter.
  • 28 funds opened new Niagen Bioscience positions in Q2 2024 and 16 closed out, a net change of +12 holders.
  • The largest Niagen Bioscience buyer in Q2 2024 was BlackRock, an estimated $7.41M added.
  • The largest Niagen Bioscience seller in Q2 2024 was Millennium Management, an estimated $1.31M sold.

Based on aggregated 13F filings for Q2 2024.